Activating presynaptic group II metabotropic @entity2227 (mGlu II) receptors reduces synaptic @entity2227 release. Attenuating glutamatergic transmission without blocking ionotropic @entity2227 receptors, thus avoiding unfavorable psychomimetic side effects, makes mGlu II receptor agonists a promising target in treating @entity75 @entity1 . Neuroprotective effects of @entity15366 were investigated in @entity35 following @entity130 ( @entity130 ). At 30 min after @entity130 , @entity35 received a single intraperitoneal injection of @entity15366 (10 mg/kg/body weight) or @entity1219 . Changes in EEG activity and pericontusional cortical perfusion were determined before @entity130 , at 4, 24, and 48 h, and 7 days after @entity130 . @entity2657 and @entity2981 volume were determined at 24 h and 7 days after @entity130 , respectively. Before brain removal pericontusional cortical @entity2227 , @entity413 , and @entity880 were measured via microdialysis. During the early period following @entity130 , EEG activity and cortical perfusion were significantly reduced in @entity35 receiving @entity15366 . At 7 days, cortical perfusion was significantly increased in @entity35 treated with @entity15366 , while EEG activity was depressed as in control @entity35 . While @entity2657 remained unchanged at 24 h, cortical @entity2981 was significantly decreased by 56% at 7 days after @entity130 . Cortical @entity2227 , @entity413 , and @entity880 were not influenced. Significant reductions in EEG activity and @entity2981 volume by @entity15366 do not appear mediated by @entity536 and @entity73 . Overall, an additional decrease in cortical perfusion seems to interfere with the anti- @entity4 potential of @entity15366 during the early period following @entity130 , while an increase in perfusion in @entity15366 -treated @entity35 at 7 days might contribute to tissue protection.

Effects of @entity15366 , a selective group II metabotropic @entity2227 receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical @entity2227 , XXXX , and @entity880 levels in @entity75 @entity35 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity2657 :: ('MESH:D001929', 'Disease') :: ['Brain edema', 'brain edema'] @entity75 :: ('MESH:D001927', 'Disease') :: ['brain-injured'] @entity1219 :: ('CHEBI:26710', 'Chemical') :: ['NaCl'] @entity73 :: ('MESH:D003072', 'Disease') :: ['energetic impairment'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edematous'] @entity536 :: ('MESH:C538265', 'Disease') :: ['attenuated excitotoxicity'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity15366 :: ('MESH:C118218', 'Chemical') :: ['LY379268'] @entity2981 :: ('MESH:D003288', 'Disease') :: ['contusion'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity130 :: ('MESH:D014947', 'Disease') :: ['CCI', 'trauma', 'controlled cortical impact injury']
@entity413 :: (MESH:D005947,Chemical) :: ['glucose']
